Addex stock falls as mid-stage study of dipraglurant in eye movement disorder fails
seekingalpha.com
finance
2022-05-27 10:39:12

gorodenkoff/iStock via Getty Images Addex Therapeutics (NASDAQ:ADXN) (OTC:ADDXF) said a phase 2a feasibility trial of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its goals. Blepharospasm is a rare neurological disorder affecting muscles around the eye which leads to blinking or other eyelid movements, such as twitching, which cannot be controlled. The trial enrolled 15 patients and its's main goal was to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
